The effect of a corticosteroid cream and a barrier-strengthening moisturizer in hand eczema. A double-blind, randomized, prospective, parallel group clinical trial

• Published in: Journal of the European Academy of Dermatology and Venereology Vol. 26; no. 5; pp. 597 - 601
• Main Authors: Lodén, M., Wirén, K., Smerud, K.T., Meland, N., Hønnås, H., Mørk, G., Lützow-Holm, C., Funk, J., Meding, B.
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01-05-2012
• Subjects: Betamethasone - administration & dosage; Betamethasone - therapeutic use; Double-Blind Method; Eczema - drug therapy; Eczema - physiopathology; Glucocorticoids - administration & dosage; Glucocorticoids - therapeutic use; Humans; Medicin och hälsovetenskap; Patient Compliance; Quality of Life
• ISSN: 0926-9959; 1468-3083; 1468-3083
• DOI: 10.1111/j.1468-3083.2011.04128.x

Background  Hand eczema is a common and persistent disease with a relapsing course. Clinical data suggest that once daily treatment with corticosteroids is just as effective as twice daily treatment.
Objectives  The aim of this study was to compare once and twice daily applications of a strong corticosteroid cream in addition to maintenance therapy with a moisturizer in patients with a recent relapse of hand eczema.
Methods  The study was a parallel, double‐blind, randomized, clinical trial on 44 patients. Twice daily application of a strong corticosteroid cream (betamethasone valerate 0.1%) was compared with once daily application, where a urea‐containing moisturizer was substituted for the corticosteroid cream in the morning. The investigator scored the presence of eczema and the patients judged the health‐related quality of life (HRQoL) using the Dermatology Life Quality Index (DLQI), which measures how much the patient’s skin problem has affected his/her life over the past week. The patients also judged the severity of their eczema daily on a visual analogue scale.
Results  Both groups improved in terms of eczema and DLQI. However, the clinical scoring demonstrated that once daily application of corticosteroid was superior to twice daily application in diminishing eczema, especially in the group of patients with lower eczema scores at inclusion.
Conclusions  Twice daily use of corticosteroids was not superior to once daily use in treating eczema. On the contrary, the clinical assessment showed a larger benefit from once daily treatment compared with twice daily, especially in the group of patients with a moderate eczema at inclusion.